John Overdeck’s Sonnet BioTherapeutics SONN Stock Holding History

John Overdeck’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,972	Closed	-$68.6K	–	4404
2025 Q3	$68.6K	Buy	+14,972	New	+$66.4K	﹤0.01%	3514
2025 Q1	–	Sell	-19,203	Closed	-$28K	–	3469
2024 Q4	$28K	Buy	+19,203	New	+$67K	﹤0.01%	3084

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

John Overdeck's SONN Position: Q4 2025 in Review

John Overdeck sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 14,972 shares — an estimated $68.6K sold.

John Overdeck first reported a position in SONN in Q4 2024 and held it in 2 quarters. The position peaked at $68.6K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

John Overdeck reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
John Overdeck sold 14,972 Sonnet BioTherapeutics shares in Q4 2025, an estimated $68.6K.
John Overdeck first reported a position in Sonnet BioTherapeutics in Q4 2024 and held it in 2 quarters.
John Overdeck's Sonnet BioTherapeutics position peaked at $68.6K in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Two Sigma Investments's 13F filing for Q4 2025, filed 17 Feb 2026.